Marshall Wace LLP Purchases New Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Marshall Wace LLP bought a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 85,580 shares of the biopharmaceutical company's stock, valued at approximately $261,000. Marshall Wace LLP owned about 0.17% of Puma Biotechnology at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in PBYI. Jane Street Group LLC grew its stake in shares of Puma Biotechnology by 103.9% in the 3rd quarter. Jane Street Group LLC now owns 32,129 shares of the biopharmaceutical company's stock valued at $82,000 after purchasing an additional 16,374 shares during the period. Barclays PLC grew its holdings in shares of Puma Biotechnology by 146.5% in the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company's stock worth $199,000 after purchasing an additional 46,370 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Puma Biotechnology during the 3rd quarter worth about $68,000. JPMorgan Chase & Co. lifted its holdings in Puma Biotechnology by 169.5% in the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 30,499 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 11,252 shares during the period. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Stock Up 2.7 %

Shares of NASDAQ PBYI traded up $0.08 during midday trading on Thursday, hitting $3.07. 402,320 shares of the stock traded hands, compared to its average volume of 440,304. The business has a 50 day moving average price of $3.12 and a two-hundred day moving average price of $3.04. Puma Biotechnology, Inc. has a one year low of $2.23 and a one year high of $5.20. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The company has a market cap of $152.37 million, a PE ratio of 6.40 and a beta of 1.29.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. On average, equities analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PBYI. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 3rd. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.